US5476659A
(en)
*
|
1982-11-09 |
1995-12-19 |
The Scripps Research Institute |
Cancerous B cell treatment using substituted nucleoside derivatives
|
US5851526A
(en)
*
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
US5776093A
(en)
*
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
JPH05507851A
(ja)
*
|
1990-06-22 |
1993-11-11 |
イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー |
免疫抑制抗―cd4―関連抗体を用いたモノクローナル抗体の改良された腹水生産
|
US5277892A
(en)
*
|
1990-08-08 |
1994-01-11 |
Rhomed Incorporated |
In vivo lymphocyte tagging
|
US5965709A
(en)
*
|
1991-08-14 |
1999-10-12 |
Genentech, Inc. |
IgE antagonists
|
US5994514A
(en)
*
|
1991-08-14 |
1999-11-30 |
Genentech, Inc. |
Immunoglobulin variants
|
US6329509B1
(en)
*
|
1991-08-14 |
2001-12-11 |
Genentech, Inc. |
Anti-IgE antibodies
|
US6699472B2
(en)
|
1991-08-14 |
2004-03-02 |
Genentech, Inc. |
Method of treating allergic disorders
|
US5643549A
(en)
*
|
1992-02-20 |
1997-07-01 |
Rhomed Incorporated |
Leukostimulatory agent for in vivo leukocyte tagging
|
AU5845594A
(en)
*
|
1992-11-13 |
1994-06-08 |
Scripps Research Institute, The |
Cancerous b cell treatment using substituted nucleoside derivatives
|
EP0675734A4
(en)
*
|
1992-12-21 |
1997-05-07 |
Tanox Biosystems Inc |
ALLERGY SPECIFIC, MONOCLONAL IgA ANTIBODIES AND SIMILAR PRODUCTS FOR ALLERGY TREATMENT.
|
ES2219646T5
(es)
*
|
1993-02-22 |
2008-11-01 |
Abraxis Bioscience, Inc. |
Metodos para la administracion in vivo de compuestos biologicos y composiciones utiles para los mismos.
|
US20030133955A1
(en)
*
|
1993-02-22 |
2003-07-17 |
American Bioscience, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
US20070122465A1
(en)
*
|
1993-02-22 |
2007-05-31 |
Desai Neil P |
Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
US20030068362A1
(en)
*
|
1993-02-22 |
2003-04-10 |
American Bioscience, Inc. |
Methods and formulations for the delivery of pharmacologically active agents
|
US20030073642A1
(en)
*
|
1993-02-22 |
2003-04-17 |
American Bioscience, Inc. |
Methods and formulations for delivery of pharmacologically active agents
|
US5800991A
(en)
*
|
1994-03-11 |
1998-09-01 |
University Of Kentucky Research Foundation |
Nucleotide or nucleoside photoaffinity compound modified antibodies, methods for their manufacture and use thereof as diagnostics and therapeutics
|
US5596081A
(en)
*
|
1994-03-11 |
1997-01-21 |
University Of Kentucky Research Foundation |
Nucleotide or nucleoside photoaffinity compound modified antibodies, methods for their manufacture and use thereof as diagnostics and therapeutics
|
US6037453A
(en)
*
|
1995-03-15 |
2000-03-14 |
Genentech, Inc. |
Immunoglobulin variants
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US20040197326A1
(en)
*
|
1995-07-27 |
2004-10-07 |
Genentech, Inc. |
Method for treatment of allergic asthma
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
JP4865937B2
(ja)
*
|
1997-06-27 |
2012-02-01 |
アブラクシス バイオサイエンス、エルエルシー |
パクリタキセル製剤
|
US20020102208A1
(en)
*
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
MY133346A
(en)
*
|
1999-03-01 |
2007-11-30 |
Biogen Inc |
Kit for radiolabeling ligands with yttrium-90
|
CA2372603C
(en)
*
|
1999-05-07 |
2015-11-17 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
DE60042785D1
(de)
|
1999-06-09 |
2009-10-01 |
Immunomedics Inc |
Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
AU778863B2
(en)
*
|
1999-07-12 |
2004-12-23 |
Genentech Inc. |
Blocking immune response to a foreign antigen using an antagonist which binds to CD20
|
MXPA02011379A
(es)
|
2000-05-19 |
2003-06-06 |
Genentech Inc |
Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
|
CN1592645A
(zh)
*
|
2000-09-18 |
2005-03-09 |
拜奥根Idec公司 |
使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20050070689A1
(en)
*
|
2001-08-03 |
2005-03-31 |
Genentech, Inc. |
Taci and br3 polypeptides and uses thereof
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
US20050043516A1
(en)
*
|
2002-07-25 |
2005-02-24 |
Genentech, Inc. |
TACI antibodies and uses thereof
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8044180B2
(en)
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
KR20070055625A
(ko)
*
|
2002-12-16 |
2007-05-30 |
제넨테크, 인크. |
이뮤노글로불린 변이체 및 이들의 용도
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
RU2358762C9
(ru)
|
2003-04-09 |
2016-10-10 |
Джинентех, Инк. |
Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
|
DK1631313T3
(da)
*
|
2003-06-05 |
2015-06-15 |
Genentech Inc |
Kombinationsterapi for b-celle-sygdomme
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
EP1964847A3
(en)
|
2003-06-25 |
2008-09-17 |
Peregrine Pharmaceuticals, Inc. |
Method and apparatus for continuous large-scale radiolabeling of proteins
|
EP1649288A1
(en)
*
|
2003-07-29 |
2006-04-26 |
Genentech, Inc. |
Assay for human anti cd20 antibodies and uses therefor
|
US20050053602A1
(en)
*
|
2003-08-29 |
2005-03-10 |
Genentech, Inc. |
Therapy of ocular disorders
|
CN1917901A
(zh)
*
|
2003-12-19 |
2007-02-21 |
健泰科生物技术公司 |
自身免疫病疗法中cd20的检测
|
MXPA06006865A
(es)
*
|
2003-12-19 |
2006-08-23 |
Genentech Inc |
Deteccion de cd20 en rechazo de transplante.
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US8883160B2
(en)
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
CA2562243A1
(en)
*
|
2004-04-16 |
2005-12-08 |
Genetech, Inc. |
Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
|
JP2007532681A
(ja)
*
|
2004-04-16 |
2007-11-15 |
ジェネンテック・インコーポレーテッド |
B細胞の枯渇を増大させる方法
|
CA2564529A1
(en)
*
|
2004-05-05 |
2005-12-15 |
Genentech, Inc. |
Preventing autoimmune disease
|
MXPA06012601A
(es)
|
2004-05-10 |
2007-05-10 |
Macrogenics Inc |
Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
|
DOP2005000108A
(es)
*
|
2004-06-04 |
2007-06-15 |
Genentech Inc |
Method for treating lupus
|
KR20150092374A
(ko)
*
|
2004-06-04 |
2015-08-12 |
제넨테크, 인크. |
다발성 경화증의 치료 방법
|
AU2005267028A1
(en)
*
|
2004-07-22 |
2006-02-02 |
Genentech, Inc. |
Method of treating Sjogren's syndrome
|
BR122018016031B8
(pt)
|
2004-08-04 |
2021-07-27 |
Applied Molecular Evolution Inc |
processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada
|
EP1812060A2
(en)
*
|
2004-10-05 |
2007-08-01 |
Genentech, Inc. |
Method for treating vasculitis
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
MX2007008218A
(es)
*
|
2005-01-13 |
2007-08-17 |
Genentech Inc |
Procedimiento de tratamiento.
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
US20060246975A1
(en)
*
|
2005-04-07 |
2006-11-02 |
Frank J. Pellegrini |
Character matching game
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
BRPI0612972A2
(pt)
*
|
2005-04-22 |
2010-12-14 |
Genentech Inc |
mÉtodo para tratar doenÇa de alzheimer, mÉtodo para tratar demÊncia, artigo de fabricaÇço e usos de um anticorpo cd20
|
AU2006251647A1
(en)
*
|
2005-05-20 |
2006-11-30 |
Genentech, Inc. |
Pretreatment of a biological sample from an autoimmune disease subject
|
BRPI0614183A2
(pt)
|
2005-07-25 |
2011-03-15 |
Trubion Pharmaceuticals Inc |
uso de dose única de moléculas de ligação especìficas para cd20
|
US20080279850A1
(en)
*
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
CN105012953B
(zh)
|
2005-07-25 |
2018-06-22 |
阿普泰沃研发有限责任公司 |
用cd37-特异性和cd20-特异性结合分子减少b-细胞
|
WO2007021841A2
(en)
|
2005-08-10 |
2007-02-22 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
KR100693340B1
(ko)
|
2005-08-12 |
2007-03-09 |
삼성전자주식회사 |
화상 형성 장치
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
ES2618543T3
(es)
*
|
2005-11-23 |
2017-06-21 |
Genentech, Inc. |
Métodos y composiciones relacionados con ensayos de linfocitos B
|
EP2021029B1
(en)
|
2006-05-26 |
2014-06-11 |
MacroGenics, Inc. |
Humanized fc gamma riib-specific antibodies and methods of use thereof
|
RU2487888C2
(ru)
|
2006-06-12 |
2013-07-20 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи |
Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
|
EP2505209A1
(en)
|
2006-06-26 |
2012-10-03 |
MacroGenics, Inc. |
Fcgamma-RIIB-specific antibodies and methods of the use thereof
|
CA2656224C
(en)
|
2006-06-26 |
2018-01-09 |
Macrogenics, Inc. |
Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
AU2008211199A1
(en)
|
2007-01-26 |
2008-08-07 |
The Regents Of The University Of Colorado |
Methods of modulating immune function
|
KR20190140090A
(ko)
|
2007-07-09 |
2019-12-18 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
EP2233149B1
(en)
|
2007-10-16 |
2016-02-10 |
ZymoGenetics, Inc. |
Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for treatment of autoimmune disease
|
US7914785B2
(en)
*
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
EP2252631B1
(en)
|
2008-04-02 |
2016-04-13 |
MacroGenics, Inc. |
Bcr-complex-specific antibodies and methods of using same
|
KR101606386B1
(ko)
|
2008-04-02 |
2016-03-25 |
마크로제닉스, 인크. |
Her2/neu-특이적 항체 및 그것의 사용 방법
|
ATE513856T1
(de)
|
2008-04-11 |
2011-07-15 |
Emergent Product Dev Seattle |
Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
JP2012508774A
(ja)
*
|
2008-11-13 |
2012-04-12 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Cd37免疫治療薬併用療法およびその使用
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
US20110142836A1
(en)
*
|
2009-01-02 |
2011-06-16 |
Olav Mella |
B-cell depleting agents for the treatment of chronic fatigue syndrome
|
KR20200111282A
(ko)
|
2009-08-11 |
2020-09-28 |
제넨테크, 인크. |
글루타민-비함유 세포 배양 배지에서의 단백질의 생성
|
HUE036549T2
(hu)
|
2009-10-07 |
2018-07-30 |
Macrogenics Inc |
A fukozilezés mértékének megváltozása miatt javított effektor funkciót mutató, Fc-régiót tartalmazó polipeptidek, valamint eljárások alkalmazásukra
|
MX341687B
(es)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
BR112012022210B1
(pt)
|
2010-03-04 |
2021-08-17 |
Macrogenics, Inc |
Anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
WO2013085893A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
ES2819573T3
(es)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
WO2015130416A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
CN107428837A
(zh)
|
2015-04-22 |
2017-12-01 |
免疫医疗公司 |
循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
|
KR102647100B1
(ko)
|
2015-05-30 |
2024-03-13 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 스캐폴드 및 이를 포함하는 세포-표적화 분자
|
CN113999312A
(zh)
|
2015-06-24 |
2022-02-01 |
豪夫迈·罗氏有限公司 |
具有定制亲和力的抗转铁蛋白受体抗体
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
CA2999138C
(en)
|
2015-09-21 |
2024-05-21 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
PE20181004A1
(es)
|
2015-10-02 |
2018-06-26 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
CA3011372A1
(en)
|
2016-02-10 |
2017-08-17 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
CR20180484A
(es)
|
2016-04-15 |
2019-03-05 |
Macrogenics Inc |
Moléculas de unón b7-h3 novedosas, conjugados anticuerpos-fármaco de los mismos y métodos de uso de los mismos
|
JP7379795B2
(ja)
|
2016-04-27 |
2023-11-15 |
イミューノメディクス、インコーポレイテッド |
チェックポイント阻害薬に再発/耐性を示す腫瘍を治療するための抗Trop-2-SN-38抗体薬物複合体の効果
|
WO2018183041A1
(en)
|
2017-03-27 |
2018-10-04 |
Immunomedics, Inc. |
Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
|
CN110352201A
(zh)
|
2017-04-03 |
2019-10-18 |
免疫医疗公司 |
用于癌症疗法的抗体药物缀合物的皮下施用
|